Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Revenio Group Oyj
  6. News
  7. Summary
    REG1V   FI0009010912

REVENIO GROUP OYJ

(REG1V)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Revenio Group Corporation: Appointment to Revenio's Leadership Team

05/28/2021 | 04:46am EST

Revenio Group Corporation, Stock exchange release, May 28, 2021 at 11.45

Appointment to Revenio’s Leadership Team

Dr Kate Taylor MBBS MPH, (b. 1971), Director of Eye Care Solutions, has been appointed to Revenio’s Leadership Team. She is the Co-Founder of Oculo, acquired by Revenio in April.

Kate is a medical doctor who initially trained as an ophthalmologist and holds an MPH from Johns Hopkins University as a Fulbright Scholar. She has worked in strategy, policy and advocacy with McKinsey & Company, the World Economic Forum’s Global Health Initiative, International AIDS Vaccine Initiative, and GlaxoSmithKline Biologicals.

Kate Taylor also serves on the Australian Digital Health Agency's Clinical and Technical Advisory Committee and the Australian Independent Hospital Pricing Authority. Previous board experience: (Australia) Mental Health CRC; (international) Roll Back Malaria, Stop TB, and the GAVI Alliance.

As of May 28, 2021, Revenio’s Leadership Team members are: CEO Jouni Toijala (chair), R&D Director of Imaging Devices Giuliano Barbaro, Operations Director Ari Isomäki, Sales and Marketing Director Tomi Karvo, CFO Robin Pulkkinen, R&D Director of Tonometers Mika Salkola and Director of Eye Care Solutions Kate Taylor, and QA Director Heli Valtanen.

Revenio Group Corporation Plc
Board of Directors

For further information, please contact:
CEO Jouni Toijala, tel. +358 50 484 0085 jouni.toijala@revenio.fi

CFO Robin Pulkkinen, tel. +358 50 505 9932 robin.pulkkinen@revenio.fi

www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA) Principal media
www.revenio.fi

The Revenio Group in brief
Revenio is a global leader in ophthalmological devices and solutions. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, Revenio Group’s eye care software platform Oculo combines clinical communication, telehealth, remote patient monitoring and data-analytics capabilities.

The Revenio Group comprises Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, Revenio Research Oy, Revenio Australia Pty Ltd, Done Medical Oy, and Oscare Medical Oy.

In 2020, the Group's net sales totaled EUR 61.1 million, with its operating profit standing at MEUR 17.1. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

© Modular Finance, source Nordic Press Releases

All news about REVENIO GROUP OYJ
11/26REVENIO GROUP CORPORATION : Revenio Group's financial reporting and Annual General Meeting..
AQ
11/16REVENIO GROUP CORPORATION : The Chairman of the Board of Revenio will resign at the spring..
AQ
10/21REVENIO GROUP CORPORATION : Interim report January 1 - September 30, 2021
AQ
10/19REVENIO GROUP CORPORATION : Invitation to Revenio Group Corporation's audiocast and teleco..
AQ
09/20REVENIO OYJ : Group Corporation - Managers' Transactions
AQ
08/05REVENIO GROUP CORPORATION : Half-year financial report 1 January-30 June 2021
AQ
08/05Revenio Group Oyj Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/04REVENIO GROUP CORPORATION : Revenio updates its financial guidance for 2021
AQ
08/04Revenio Group Corporation Reaffirms Earnings Guidance for the Full Year 2021
CI
07/27REVENIO GROUP CORPORATION : Invitation to Revenio's audiocast and teleconference in relati..
AQ
More news
Financials
Sales 2021 77,2 M 87,3 M 87,3 M
Net income 2021 17,0 M 19,2 M 19,2 M
Net Debt 2021 2,61 M 2,95 M 2,95 M
P/E ratio 2021 86,0x
Yield 2021 0,63%
Capitalization 1 460 M 1 652 M 1 651 M
EV / Sales 2021 18,9x
EV / Sales 2022 15,8x
Nbr of Employees 158
Free-Float 84,3%
Chart REVENIO GROUP OYJ
Duration : Period :
Revenio Group Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REVENIO GROUP OYJ
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 54,95 €
Average target price 59,87 €
Spread / Average Target 8,95%
EPS Revisions
Managers and Directors
Jouni Erik Toijala President & Chief Executive Officer
Robin Allan Pulkkinen Chief Financial Officer
Pekka Veikko Juhani Rönkä Chairman
Mika Salkola Director-Research & Development
Ari Isomäki Operations Director
Sector and Competitors
1st jan.Capi. (M$)
REVENIO GROUP OYJ9.24%1 652
SARTORIUS AG49.28%42 386
BIOTAGE AB (PUBL)89.21%1 906
VAREX IMAGING CORPORATION76.68%1 162
CELLAVISION AB (PUBL)15.90%932
908 DEVICES INC.-59.00%651